Richards Patricia, Riff Dennis, Kelen Robin, Stern Warren
QRxPharma, Inc., Clinical Research, Bedminster, New Jersey, USA.
J Opioid Manag. 2011 May-Jun;7(3):217-28. doi: 10.5055/jom.2011.0064.
To compare efficacy and safety profiles of an immediate-release morphine and oxycodone Dual-Opioid combination (MoxDuo) versus its individual components and versus its morphine-equivalent doses in moderate to severe postoperative pain patients.
Randomized, double-blind, 48-hour, parallel-treatment, multicenter, six-arm study of MoxDuo.
Six US centers.
Within 6 hours after bunionectomy surgery, patients were eligible if they reported pain intensity > or = 2 on the 4-point Likert scale and > or = 4 on an 11-point Numerical Pain Rating Scale (197 randomly assigned; 175 completers).
MoxDuo 12 mg/8 mg, MoxDuo 6 mg/4 mg, morphine 12 mg, oxycodone 8 mg, morphine 6 mg, or oxycodone 4 mg (all administered q6h).
Sum of pain intensity differences 0-24 hours after the first dose of study medication (SPID24) and percentage of patients with moderate to severe nausea, emesis, or dizziness.
SPID24 was significantly better in the MoxDuo 12 mg/8 mg group when compared with its individual components (morphine 12 mg [p = 0.009] and oxycodone 8 mg [p = 0.037]), and when compared with MoxDuo 6 mg/4 mg (p = 0.011; 54.3 vs 28.5, 35.7, and 30.0, respectively). MoxDuo6 mg/4 mg and its morphine-equivalent doses (morphine 12 mg and oxycodone 8 mg) had comparable analgesic effects. There was a 50-75 percent reduction in moderate to severe adverse events (AEs) commonly associated with opioids (ie, nausea, vomiting, and dizziness) in the MoxDuo 6 mg/4 mg group when compared with its morphine-equivalent dose groups.
MoxDuo produced superior analgesic effects when compared with its individual components, but comparable efficacy when compared with its morphine-equivalent doses. Common AEs were reduced at least 50 percent with MoxDuo when compared with its morphine-equivalent doses. MoxDuo may be an improved intervention in the management of moderate to severe acute pain.
比较速释吗啡和羟考酮双阿片类药物组合(MoxDuo)与其单一成分以及与其等效吗啡剂量在中重度术后疼痛患者中的疗效和安全性。
MoxDuo的随机、双盲、48小时、平行治疗、多中心、六臂研究。
美国六个中心。
拇囊炎切除术后6小时内,若患者在4分李克特量表上报告疼痛强度≥2分,且在11分数字疼痛评分量表上≥4分,则符合入选标准(随机分配197例;完成研究175例)。
MoxDuo 12毫克/8毫克、MoxDuo 6毫克/4毫克、吗啡12毫克、羟考酮8毫克、吗啡6毫克或羟考酮4毫克(均每6小时给药一次)。
首次服用研究药物后0至24小时的疼痛强度差异总和(SPID24)以及中重度恶心、呕吐或头晕患者的百分比。
与单一成分(吗啡12毫克[p = 0.009]和羟考酮8毫克[p = 0.037])相比,以及与MoxDuo 6毫克/4毫克相比(p = 0.011;分别为54.3对28.5、35.7和30.0),MoxDuo 12毫克/8毫克组的SPID24显著更好。MoxDuo 6毫克/4毫克及其等效吗啡剂量(吗啡12毫克和羟考酮8毫克)具有相当的镇痛效果。与等效吗啡剂量组相比,MoxDuo 6毫克/4毫克组中通常与阿片类药物相关的中重度不良事件(即恶心、呕吐和头晕)减少了50%至75%。
与单一成分相比,MoxDuo产生了更好的镇痛效果,但与等效吗啡剂量相比,疗效相当。与等效吗啡剂量相比,MoxDuo使常见不良事件减少了至少50%。MoxDuo可能是中重度急性疼痛管理方面的一种改进干预措施。